Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17127642 | DUAL CARTRIDGE CONTAINER APPLICATOR WITH NEEDLE PENETRATION CONNECTION TO TIP | December 2020 | September 2024 | Allow | 45 | 4 | 0 | No | No |
| 16952433 | BENEFIT AGENT DELIVERY SYSTEM COMPRISING MICROCELLS HAVING AN ELECTRICALLY ERODING SEALING LAYER | November 2020 | January 2024 | Allow | 38 | 2 | 1 | No | No |
| 16951451 | STERILE CONNECTOR AND CANNULA ASSEMBLY | November 2020 | January 2025 | Allow | 50 | 3 | 0 | No | No |
| 17087583 | Fixture For Filling Hypodermic Syringes | November 2020 | September 2023 | Allow | 34 | 2 | 0 | No | No |
| 17051579 | IMPLANTABLE ACCESS DEVICE FOR ACCESSING THE VASCULAR SYSTEM OF A HUMAN OR ANIMAL BODY, PARTICULARLY SUBCUTANEOUSLY IMPLANTABLE ACCESS PORT | October 2020 | February 2025 | Allow | 52 | 4 | 0 | No | No |
| 17048007 | SHOCK ABSORBER FOR INJECTION DEVICES | October 2020 | October 2024 | Allow | 48 | 4 | 1 | Yes | No |
| 17046403 | Tool for Removing a Cap From a Medical Injection Device | October 2020 | September 2024 | Allow | 47 | 3 | 1 | No | No |
| 17045676 | ELECTROHYDRAULIC MICROJET DRUG DELIVERY DEVICE | October 2020 | September 2023 | Allow | 36 | 3 | 0 | No | No |
| 17035989 | WEARABLE AUTO-INJECTOR DEVICES AND METHODS | September 2020 | September 2024 | Abandon | 48 | 3 | 0 | No | No |
| 17034821 | CANNULA FIXATION DEVICE | September 2020 | March 2025 | Allow | 53 | 4 | 0 | No | No |
| 17030336 | CARTRIDGE HOLDER AND MEDICINE INJECTION DEVICE COMPRSING THE SAME | September 2020 | August 2023 | Abandon | 35 | 2 | 0 | No | No |
| 16964419 | TUBE ASSEMBLY AND DISSOLVABLE TIP | July 2020 | May 2024 | Abandon | 46 | 1 | 0 | No | No |
| 16918471 | MEDICAL TUBE | July 2020 | July 2024 | Abandon | 49 | 2 | 0 | Yes | No |
| 16772565 | Therapeutic Agent Delivery Devices Having Integrated Pain Mitigation, and Methods for Using the Same | June 2020 | May 2024 | Abandon | 47 | 2 | 1 | No | No |
| 16870574 | LARYNGEAL MASK AIRWAY FOR GASTROSCOPY | May 2020 | July 2024 | Allow | 50 | 2 | 0 | No | No |
| 16741998 | CATHETER FLUSH DEVICE, SYSTEM, AND METHODS | January 2020 | June 2025 | Allow | 60 | 4 | 1 | Yes | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner DIOP, FATIMATA SAHRA works in Art Unit 3783 and has examined 16 patent applications in our dataset. With an allowance rate of 68.8%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 48 months.
Examiner DIOP, FATIMATA SAHRA's allowance rate of 68.8% places them in the 32% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by DIOP, FATIMATA SAHRA receive 2.81 office actions before reaching final disposition. This places the examiner in the 78% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by DIOP, FATIMATA SAHRA is 48 months. This places the examiner in the 10% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a -2.6% benefit to allowance rate for applications examined by DIOP, FATIMATA SAHRA. This interview benefit is in the 9% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 27.8% of applications are subsequently allowed. This success rate is in the 52% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 41.7% of cases where such amendments are filed. This entry rate is in the 65% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 73% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 45% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 51% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.